BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15332558)

  • 1. [Gastrointestinal cancer].
    Takahashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
    Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
    Grotowski M
    Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection.
    Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E
    J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA and CA 19-9 as prognostic indexes in colorectal cancer.
    Forones NM; Tanaka M
    Hepatogastroenterology; 1999; 46(26):905-8. PubMed ID: 10370636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of serum tumor markers in asymptomatic individuals.
    Eleftheriadis N; Papaloukas C; Pistevou-Gompaki K
    J BUON; 2009; 14(4):707-10. PubMed ID: 20148467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
    Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
    Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
    Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
    Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer.
    Ucar E; Semerci E; Ustun H; Yetim T; Huzmeli C; Gullu M
    Adv Ther; 2008 Oct; 25(10):1075-84. PubMed ID: 18821070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer].
    Sandelewski A; Kokocińska D; Partyka R; Kocot J; Starzewski J; Chanek I; Jałowiecki P
    Pol Merkur Lekarski; 2005 Jun; 18(108):647-50. PubMed ID: 16124375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
    Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
    Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
    Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.